

Press release January 27, 2022, 08.30 CET.

Sedana Medical's Sedaconda ACD recommended by NICE

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the National Institute for Health and Care Excellence (NICE) has issued positive guidance recommending Sedaconda ACD as a cost-saving option for delivering inhaled sedation in intensive care as an alternative to intravenous sedation.

Sedaconda ACD is recommended as an option for delivering inhaled sedation in intensive care in England and Wales when volatile anaesthetics are being considered. Cost modelling shows cost savings compared with intravenous sedation of almost £4,000 per adult patient (30-day time horizon for adult patients needing mechanical ventilation for 24 hours or longer in intensive care).

"The recommendation from NICE is a major milestone for Sedana Medical. After showing meaningful benefits of Sedaconda (isoflurane) versus intravenous sedation in our clinical trial SED001, NICE has now confirmed that the use of Sedaconda ACD leads to considerable cost savings compared to intravenous sedation. We are looking forward to continuing our good collaboration with NICE and are pleased that the NHS in England and Wales will have a new cost-effective alternative to provide inhaled sedation to critically ill patients in the ICU," said Johannes Doll, CEO of Sedana Medical.

NICE commissioned an external assessment centre (EAC) to review the evidence. This recommendation is based on clinical evidence comprising 21 studies and is supported by the economic model submitted to NICE, which demonstrated cost-savings.

For further detail, please see: www.nice.org.uk/guidance/mtg65

For additional information, please contact:

Johannes Doll, CEO, +46 76 303 66 66
ir@sedanamedical.com

Sedana Medical is listed on Nasdaq First North Growth Market in Stockholm.
The company's Certified Adviser is Erik Penser Bank, +46 8 463 83 00, certifiedadviser@penser.se.

About Sedana Medical

Sedana Medical AB (publ) is a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve the patient's life during and beyond sedation. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care.

Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, the Nordic, and Spain. In other parts of Europe as well as in Asia, Australia, Canada, and South and Central America, the company works with external distributors.

Sedana Medical was founded in 2005, is listed on Nasdaq First North Growth Market (SEDANA) and headquartered in Stockholm, Sweden.